GET DAILY SIGNALSWhy Is Harrow, Inc. (HROW) Stock Up +15.18% Today?
Key Takeaways
- Harrow, Inc. shares jumped roughly 15.18% after the company reported third-quarter 2026 results that beat Wall Street estimates.
- The primary catalyst was an earnings-driven move: record quarterly revenue and better-than-expected GAAP earnings per share.
- Branded product revenue surged 62% year over year, led by the dry-eye treatment VEVYE and the ocular-inflammation drug TRIESENCE.
- Management reaffirmed its full-year revenue guidance of $350 million to $365 million and said the fourth quarter should be its strongest on record.
- The rally came even as the company lowered its adjusted EBITDA outlook, signaling investors focused on accelerating branded growth rather than near-term margins.
- Traders are now watching the earnings conference call for details on the TYRVAYA launch, the EBITDA revision, and branded growth sustainability.
- For additional context, explore Harrow's Price Targets, Earnings, and Forecast pages.
- Curious about automated strategies? Explore Trending AI Robots to see which AI trading bots are performing best right now.
Opening Summary
HROW — Harrow, Inc., a Nashville-based provider of ophthalmic pharmaceutical products for conditions affecting the front and back of the eye — climbed sharply in Tuesday's session, gaining roughly 15.18% to trade near $31.64, up from a prior close of $27.47. The advance was driven by the company's third-quarter 2026 earnings release, which showed record revenue, a return to GAAP profitability, and accelerating growth across its branded product portfolio. The market reaction reflects investor enthusiasm for Harrow's continued shift toward higher-margin branded drugs, even as management trimmed its full-year adjusted EBITDA outlook.
Earnings Results and Guidance
The rally was anchored in a strong quarterly report. Harrow posted total revenue of $99.3 million, up 39% year over year and above analyst consensus. GAAP earnings per share came in at $0.25, comfortably beating the roughly $0.19 expected. GAAP net income swung to a $9.8 million profit from a $17.3 million net loss in the second quarter, marking a notable turnaround on the bottom line.
Just as important, the company reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million, and executives described the fourth quarter as poised to be the strongest in Harrow's history. That confidence, combined with the revenue beat, gave investors a clear reason to bid the stock higher despite earlier misses in the first two quarters of the year.
Branded Product Momentum
The standout feature of the quarter was the strength of Harrow's branded portfolio. Branded revenue rose 62% year over year to $83.5 million, representing roughly 84% of total revenue. VEVYE, the company's water-free cyclosporine treatment for dry eye disease, generated a record $39.7 million, while TRIESENCE crossed $10 million in quarterly revenue for the first time under Harrow's ownership. IHEEZO, an ocular anesthetic heading into its historically strongest seasonal period, also contributed $25.3 million.
This mix shift toward branded, higher-margin products is a core part of the bullish narrative. Investors appear to be rewarding the company's progress in converting demand into revenue — a theme management has emphasized as the second half of 2026 plays out.
Guidance Caution and Margin Pressures
The advance was not without caveats. Harrow lowered its full-year adjusted EBITDA guidance to more than $40 million, down sharply from the prior $80 million to $100 million range, citing increased commercial and R&D investment plus first-half shortfalls. Gross margins also came in below management's own expectations, weighed down by lower-margin compounding revenue and product mix.
Still, the stock's reaction suggests traders chose to look past those headwinds. The reaffirmed revenue outlook and the expectation of a record fourth quarter outweighed concerns about near-term profitability, a dynamic typical of growth-stage specialty pharmaceutical names where top-line momentum is the primary focus.
Market Context and Trading Activity
The move was accompanied by elevated trading activity, consistent with an earnings-driven repricing. Harrow's stock had been under pressure heading into the print — shares were down sharply over the prior three months and had seen two consecutive quarterly disappointments — so the beat triggered a forceful relief rally as short-term positioning and negative sentiment unwound.
The advance also stood apart from broader market action. While sector and index moves on the day were comparatively muted, Harrow's double-digit gain was clearly company-specific, driven by fundamentals rather than a general risk-on rotation across healthcare or small-cap names.
What Comes Next for HROW
Attention now turns to execution. Investors will be listening to management's earnings call for detail on the adjusted EBITDA revision, the launch trajectory of TYRVAYA — the recently acquired nasal-spray dry eye treatment expected to contribute more than $30 million in 2027 — and the sustainability of VEVYE and TRIESENCE growth. The company's pipeline, including the planned OPUVIZ biosimilar launch in 2027 and the G-MELT regulatory filing, also remains in focus.
Key risks include continued margin compression, higher spending, a still-heavy debt load, and the need to sustain the branded growth that underpinned this quarter's beat. Whether the stock can hold its gains will likely depend on fourth-quarter results confirming management's guidance that the strongest quarter is still ahead.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are currently among the strongest performers. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only those delivering standout results under present market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Explore the page to see which automated strategies are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HROW's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for HROW turned positive on October 20, 2026. Looking at past instances where HROW's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HROW's RSI Indicator exited the oversold zone, 34 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 56 cases where HROW's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on HROW as a result. In 64 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +12.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where HROW advanced for three days, in 236 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
HROW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HROW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for HROW entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. HROW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HROW's P/B Ratio (66.319) is slightly higher than the industry average of (6.379). P/E Ratio (-27.162) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (183.387).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a pharmaceutical company
Industry PharmaceuticalsGeneric
Advertisement